{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:58:18Z","timestamp":1757624298150,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW-114-TDU-B-221-144005"],"award-info":[{"award-number":["MOHW-114-TDU-B-221-144005"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2640-B-006-004"],"award-info":[{"award-number":["113-2640-B-006-004"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16325-6","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T19:27:11Z","timestamp":1755977231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The RASAL2 variant promotes aberrant RAS signaling and resistance to anti-EGFR therapy in colorectal cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Yu-Min","family":"Yeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsuan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-Chan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ting","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Ru","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"16325_CR1","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl. J. Med. 360, 1408\u20131417 (2009).","journal-title":"N Engl. J. Med."},{"key":"16325_CR2","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard, J. Y. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28, 4697\u20134705 (2010).","journal-title":"J. Clin. Oncol."},{"key":"16325_CR3","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.bjc.6606008","volume":"103","author":"F Di Fiore","year":"2010","unstructured":"Di Fiore, F., Sesboue, R., Michel, P., Sabourin, J. C. & Frebourg, T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br. J. Cancer. 103, 1765\u20131772 (2010).","journal-title":"Br. J. Cancer"},{"key":"16325_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdn541","volume":"20","author":"F Perrone","year":"2009","unstructured":"Perrone, F. et al. PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 20, 84\u201390 (2009).","journal-title":"Ann. Oncol."},{"key":"16325_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/0008-5472.CAN-08-2466","volume":"69","author":"A Sartore-Bianchi","year":"2009","unstructured":"Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851\u20131857 (2009).","journal-title":"Cancer Res."},{"key":"16325_CR6","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1634\/theoncologist.2018-0785","volume":"24","author":"A Sartore-Bianchi","year":"2019","unstructured":"Sartore-Bianchi, A. et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist 24, 1395\u20131402 (2019).","journal-title":"Oncologist"},{"key":"16325_CR7","doi-asserted-by":"publisher","first-page":"54627","DOI":"10.18632\/oncotarget.10559","volume":"7","author":"K Raghav","year":"2016","unstructured":"Raghav, K. et al. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de Novo phenomenon. Oncotarget 7, 54627\u201354631 (2016).","journal-title":"Oncotarget"},{"key":"16325_CR8","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.19.01254","volume":"37","author":"F Morano","year":"2019","unstructured":"Morano, F. et al. Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. J. Clin. Oncol. 37, 3099\u20133110 (2019).","journal-title":"J. Clin. Oncol."},{"key":"16325_CR9","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","volume":"28","author":"C Cremolini","year":"2017","unstructured":"Cremolini, C. et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann. Oncol. 28, 3009\u20133014 (2017).","journal-title":"Ann. Oncol."},{"key":"16325_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","volume":"129","author":"JL Bos","year":"2007","unstructured":"Bos, J. L., Rehmann, H. & Wittinghofer, A. GEFs and gaps: critical elements in the control of small G proteins. Cell 129, 865\u2013877 (2007).","journal-title":"Cell"},{"key":"16325_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3389\/fonc.2019.01235","volume":"9","author":"B Zhou","year":"2019","unstructured":"Zhou, B., Zhu, W., Jiang, X. & Ren, C. RASAL2 plays inconsistent roles in different cancers. Front. Oncol. 9, 1235 (2019).","journal-title":"Front. Oncol."},{"key":"16325_CR12","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3892\/ol.2017.5581","volume":"13","author":"Z Jia","year":"2017","unstructured":"Jia, Z., Liu, W., Gong, L. & Xiao, Z. Downregulation of RASAL2 promotes the proliferation, epithelial-mesenchymal transition and metastasis of colorectal cancer cells. Oncol. Lett. 13, 1379\u20131385 (2017).","journal-title":"Oncol. Lett."},{"key":"16325_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s13046-019-1290-0","volume":"38","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation. J. Exp. Clin. Cancer Res. 38, 296 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"16325_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13046-024-02987-z","volume":"43","author":"YT Huang","year":"2024","unstructured":"Huang, Y. T. et al. Tight junction protein cingulin variant is associated with cancer susceptibility by overexpressed IQGAP1 and Rac1-dependent epithelial-mesenchymal transition. J. Exp. Clin. Cancer Res. 43, 65 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"16325_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2002","unstructured":"Zhang, W. & Liu, H. T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell. Res. 12, 9\u201318 (2002).","journal-title":"Cell. Res."},{"key":"16325_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"16325_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/path.4273","volume":"232","author":"SA Smith","year":"2014","unstructured":"Smith, S. A., French, T. & Hollingsworth, S. J. The impact of germline mutations on targeted therapy. J. Pathol. 232, 230\u2013243 (2014).","journal-title":"J. Pathol."},{"key":"16325_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccr.2013.08.004","volume":"24","author":"SK McLaughlin","year":"2013","unstructured":"McLaughlin, S. K. et al. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell. 24, 365\u2013378 (2013).","journal-title":"Cancer Cell."},{"key":"16325_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/gcc.23133","volume":"62","author":"C Wills","year":"2023","unstructured":"Wills, C. et al. Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer. Genes Chromosomes Cancer. 62, 332\u2013341 (2023).","journal-title":"Genes Chromosomes Cancer"},{"key":"16325_CR20","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1158\/1078-0432.CCR-21-0714","volume":"27","author":"SB Koh","year":"2021","unstructured":"Koh, S. B. et al. RASAL2 confers collateral MEK\/EGFR dependency in chemoresistant triple-negative breast cancer. Clin. Cancer Res. 27, 4883\u20134897 (2021).","journal-title":"Clin. Cancer Res."},{"key":"16325_CR21","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.2147\/CMAR.S292342","volume":"13","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. Novel resistance mechanisms to osimertinib analysed by whole-exome sequencing in non-small cell lung cancer. Cancer Manag Res. 13, 2025\u20132032 (2021).","journal-title":"Cancer Manag Res."},{"key":"16325_CR22","doi-asserted-by":"crossref","unstructured":"Wee, P. & Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 9 (2017).","DOI":"10.3390\/cancers9050052"},{"key":"16325_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13046-019-1230-z","volume":"38","author":"V Belli","year":"2019","unstructured":"Belli, V. et al. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. J. Exp. Clin. Cancer Res. 38, 236 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"16325_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2159-8290.CD-21-0072","volume":"12","author":"KW Song","year":"2022","unstructured":"Song, K. W. et al. RTK-Dependent inducible degradation of mutant PI3Kalpha drives GDC-0077 (Inavolisib) efficacy. Cancer Discov. 12, 204\u2013219 (2022).","journal-title":"Cancer Discov"},{"key":"16325_CR25","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/febs.14773","volume":"286","author":"SM Park","year":"2019","unstructured":"Park, S. M. et al. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells. FEBS J. 286, 1305\u20131318 (2019).","journal-title":"FEBS J."},{"key":"16325_CR26","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz, S. et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat. Med. 31, 901\u2013908 (2025).","journal-title":"Nat. Med."},{"key":"16325_CR27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl. J. Med. 381, 1632\u20131643 (2019).","journal-title":"N Engl. J. Med."},{"key":"16325_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2217\/14622416.9.2.235","volume":"9","author":"CT Fan","year":"2008","unstructured":"Fan, C. T., Lin, J. C. & Lee, C. H. Taiwan biobank: a project aiming to aid taiwan\u2019s transition into a biomedical Island. Pharmacogenomics 9, 235\u2013246 (2008).","journal-title":"Pharmacogenomics"},{"key":"16325_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"C Genomes Project","year":"2015","unstructured":"Genomes Project, C. et al. A global reference for human genetic variation. Nature 526, 68\u201374 (2015).","journal-title":"Nature"},{"key":"16325_CR30","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/bioinformatics\/btv009","volume":"31","author":"HA Shihab","year":"2015","unstructured":"Shihab, H. A. et al. An integrative approach to predicting the functional effects of non-coding and coding sequence variation. Bioinformatics 31, 1536\u20131543 (2015).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16325-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16325-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16325-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:40:44Z","timestamp":1757421644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16325-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16325"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16325-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"RASAL2 variant mediates anti-EGFR resistance in colorectal cancer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Running title"}},{"value":"3068, 6 figures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Word count"}},{"value":"The authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Figures and Figure Legends.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"31076"}}